This week Hilary Clinton and Marco Rubio announced their
candidacies for President of the United States.
This puts them alongside Jeb Bush, Scott Walker and I’m not sure who
else. One thing all these candidates
have in common is that not one of them has mentioned antibiotics – at least as
far as I know. Do any of you know
anything different?
So here we are.
Antibiotic resistance is killing a minimum of 23,000 Americans every
year according to the CDC. (I think that
is a gross underestimate of reality.) The FDA just published a study showing
large increase in antibiotic use on US farms – but they don’t know how or why
the antibiotics are used. They have issued guidelines that ask industry to
voluntarily withdraw growth promotion from labels for animal antibiotics – but
they refuse to simply ban such use for reasons that are unclear (besides
politics that is). Europe
not only has instituted such a ban but does a remarkable job of following
antibiotic use in animals. Have any
of the candidates mentioned anything about the FDA and antibiotic use in
animals?
President Obama has released a plan
to combat antibiotic resistance that was enshrined in his congressional budget
request where he asks for a doubling, but still completely inadequate, level of
funding for his efforts. I have not seen
any comments from any of the candidates on this plan.
No one is talking about one of the key tasks that lie before
us globally and as a nation. We have to
make sure that antibiotic research provides some sort of return on investment
for those who engage in these activities and are successful. Many of the ways
we can accomplish this have been discussed ad
nauseum both here in this blog and elsewhere. Among them –
1.
Support for R&D including the most expensive
piece- late stage clinical trials. This
has been mainly borne by BARDA in the US
and IMI in Europe. Such support reduces
the investment required to bring needed antibiotics to the marketplace.
2.
Pull incentives
a.
Guaranteed purchase upon approval.
b.
Wild card patent exclusivity or patent voucher -
where a company that achieves approval for a needed antibiotic is rewarded with
six months to two years of added exclusivity for a product of its choice. A good example would be Lipitor from Pfizer
where it was selling $15B per year at its peak.
c.
Prizes.
From the lack of comment by candidates, I reach the
following conclusions.
1.
Antibiotic resistance is not a priority for the
next President.
2.
Antibiotic resistance is not viewed as a
priority for voters.
3.
The candidates do not view antibiotic resistance
as an important public health threat.
4.
The candidates’ desire to distance themselves
from President Obama is greater than their desire to support or expand upon his
programs.
5.
We’re
screwed!
No comments:
Post a Comment